By Jennifer Rigby and Julie Steenhuysen (Reuters) - After producing vaccines and treatments for acute COVID-19 in record time, researchers and drugmak.
Leading drugmakers, including those who have launched pills and monoclonal antibodies for COVID-19, are having early discussions with researchers about how to target the disease.